株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:過敏性腸症候群 (IBS)

Market Spotlight: Irritable Bowel Syndrome (IBS)

発行 Datamonitor Healthcare 商品コード 594579
出版日 ページ情報 英文 49 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
注目市場の分析:過敏性腸症候群 (IBS) Market Spotlight: Irritable Bowel Syndrome (IBS)
出版日: 2019年09月05日 ページ情報: 英文 49 Pages
概要

当レポートでは、過敏性大腸症候群 (IBS) の治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法、規制環境と近年の主な出来事、現在開発中の治験の進行状況と上市スケジュール、主な治療薬の市場動向見通し (今後10年間分)、資本取引の動きなどを調査しております。

分析のポイント

疾患の背景事情

  • IBSの亜類型 (サブタイプ)

治療法

  • 緩下剤
  • 止瀉薬
  • 鎮痙薬
  • 抗うつ剤
  • セロトニン受容体作動薬
  • クロライドチャネル活性化剤
  • グアニル酸シクラーゼC作動薬
  • 抗生物質
  • オピオイド受容体
  • プロバイオティクス

疫学

上市済み医薬品

  • 各国での認証状況

パイプライン上の医薬品

間もなく生じる主な出来事

規制関連の主な出来事 (1件)

ライセンス契約・資産買収取引

母体特許

収益機会

治験情勢

  • スポンサー数:ステータス別
  • スポンサー数:フェーズ (相) 別

関連分析

  • 処方薬の情報

付録

目次
Product Code: DMKC0181355

This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 766 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 843 million prevalent cases by

2026. The approved drugs in the IBS space target chloride channel 2, calcium channel, serotonin 5-HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route. High-impact upcoming events for drugs in the IBS space comprise topline Phase II trial results for MD-7246 and an expected PDUFA date for Tenapanor.

The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 21.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall gastroenterology (non inflammatory bowel disease) space.

There have been 19 licensing and asset acquisition deals involving IBS drugs during 2014-19. The $2,905m research, development, collaboration, and license agreement signed in 2017 between Allergan and Assembly Biosciences for the worldwide rights to Assembly's microbiome GI development programs was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 66% of trials in Phase I-II, and only 34% in Phase III-IV.

The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the IBS space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for IBS, with 37 trials.

Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline and Novartis.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Laxatives
  • Antidiarrheal drugs
  • Antispasmodics
  • Antidepressants
  • Serotonin receptor agonists
  • Chloride channel activators
  • Guanylyl cyclase C agonists
  • Antibiotics
  • Opioid receptors
  • Probiotics

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Zelnorm for IBS (July 8, 2019)
  • Multiple Drugs for IBS (June 25, 2019)
  • Linzess for IBS (June 18, 2019)
  • Zelnorm for IBS (October 17, 2018)
  • Zelnorm for IBS (October 15, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • FDA Approves The First Device To Treat Pain Caused By IBS
  • Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment
  • Zelnorm Returning To US Market With Broad IBS-C Indication
  • The New Zelnorm-al: US FDA's Do-Over On Cardiovascular Safety
  • US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Alfasigma Acquires Sloan's Zelnorm
  • Deals Shaping The Medical Industry, January 2019
  • Luoxin Gets Trulance Rights In China From Synergy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of IBS, 2017-26
  • Figure 2: Prevalent cases of IBS, by age group, 2017
  • Figure 3: Overview of pipeline drugs for IBS in the US
  • Figure 4: Pipeline drugs for IBS, by company
  • Figure 5: Pipeline drugs for IBS, by drug type
  • Figure 6: Pipeline drugs for IBS, by classification
  • Figure 7: Linzess for IBS (June 18, 2019): Phase IIIb - IBS-C Abdominal Symptoms
  • Figure 8: Zelnorm for IBS (October 15, 2018): Regulatory - FDA Advisory Panel Brief
  • Figure 9: Key upcoming events in IBS
  • Figure 10: Probability of success in the IBS pipeline
  • Figure 11: Licensing and asset acquisition deals in IBS, 2014-19
  • Figure 12: Parent patents in IBS
  • Figure 13: Clinical trials in IBS
  • Figure 14: Top 10 drugs for clinical trials in IBS
  • Figure 15: Top 10 companies for clinical trials in IBS
  • Figure 16: Trial locations in IBS
  • Figure 17: IBS trials status
  • Figure 18: IBS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of IBS, 2017-26
  • Table 2: Prevalent cases of IBS, by gender, 2017
  • Table 3: Prevalence of IBS, by gender, 2017
  • Table 4: Marketed drugs for IBS
  • Table 5: Pipeline drugs for IBS in the US
  • Table 6: Zelnorm for IBS (July 8, 2019)
  • Table 7: Multiple Drugs for IBS (June 25, 2019)
  • Table 8: Linzess for IBS (June 18, 2019)
  • Table 9: Zelnorm for IBS (October 17, 2018)
  • Table 10: Zelnorm for IBS (October 15, 2018)
  • Table 11: Historical global sales, by drug ($m), 2014-18
  • Table 12: Forecasted global sales, by drug ($m), 2019-23
Back to Top